Study design (if review, criteria of inclusion for studies)
randomised double blind 2-weeks trial
Participants
22 adults with cystic fibrosis. 26 courses of treatment were initiated and 22 courses were completed.
Interventions
monotherapy with ceftazidime and aztreonam
Outcome measures
FEV1, sputum weight
Main results
Within groups, both ceftazidime and aztreonam demonstrated a significant improvement in FEV1 at 2 weeks (ceftazidime p less than 0.05; aztreonam p less than 0.01) and a decline in sputum weight at 2 weeks (ceftazidime p less than 0.05; aztreonam p less than 0.05). Between groups, for spirometry and sputum weight the only change was a slower decline in FEV1 in the aztreonam group at 42 days (p less than 0.05).